Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Wei Shen Tan, Vignesh T. Packiam(Rutgers, The State University of New Jersey), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Michael A. O’Donnell(University of Iowa Health Care), Facundo Davaro(Moffitt Cancer Center), Ryan L. Steinberg(University of Iowa), Ian M. McElree(Vanderbilt University Medical Center), Roger Li(Unknown), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center)
Cited by 38
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
1,1-Bis(3′-indolyl)-1-( <i>p</i> -chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth
|Molecular Cancer Therapeutics|2008|104